Matthew Burge
A5015610217- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Esophageal Cancer Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Lipids, and Metabolism
- Cancer Cells and Metastasis
- Cancer survivorship and care
- Cancer, Hypoxia, and Metabolism
Royal Brisbane and Women's Hospital
2016-2025
The University of Queensland
2016-2024
St Bartholomew's Hospital
2024
Royal Ottawa Mental Health Centre
2023
Prince Charles Hospital
2004-2023
QIMR Berghofer Medical Research Institute
2020-2023
Prince Charles Hospital
2023
Cancer Care Services
2019
Lyell McEwin Hospital
2018
Blandford Community Hospital
2017
KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC).This phase II open-label study involved 128 centers worldwide. Eligible patients were age ≥ 18 years and had metastatic MSI-H/dMMR CRC treated with 2 prior lines standard therapy, including fluoropyrimidine, oxaliplatin, irinotecan or without anti-vascular endothelial growth...
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. presence circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence a low risk recurrence. benefit for ctDNA-positive patients is not well understood.
Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit patients with liver metastases liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy SIRT using yttrium-90 resin microspheres metastases. were designed combined analysis overall survival.
For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in LARC.We enrolled LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery. Somatic mutations individual patient's identified via massively parallel...
In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker minimal residual disease, is powerful prognostic factor in nonmetastatic cancer (CRC). Serial analysis ctDNA CRLM could inform optimal use perioperative chemotherapy. Here, we performed validation study confirm impact observed previous discovery study.We prospectively...
This randomized, open-label trial compared the efficacy and safety of adjuvant
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, lymphocyte-activation gene 3 (LAG-3)-blocking chemotherapy in patients with previously untreated advanced gastric cancer (GC) or gastroesophageal junction (GEJC).
// Catherine E. Bond 1 , Diane M. McKeone Murugan Kalimutho 2 Mark L. Bettington 1, 3, 4 Sally-Ann Pearson Troy D. Dumenil Leesa F. Wockner 5 Matthew Burge 6 Barbara A. Leggett 4, 7 Vicki L.J. Whitehall 8 Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Signal Transduction 3 Envoi Specialist Pathologists, School of Medicine, University Cancer and Population Studies, Department Oncology, Royal Brisbane Women's Hospital,...
Abstract Background: There is strong interest in testing lifestyle interventions to improve cancer outcomes; however, the optimal methods for achieving behavior change large-scale pragmatic trials are unknown. Here, we report 1-year feasibility results exercise Canadian Cancer Trials Group CO.21 (CHALLENGE) Trial. Methods: Between 2009 and 2014, 273 high-risk stage II III colon survivors from 42 centers Canada Australia were randomized a structured program (SEP; n = 136) or health education...
Abstract Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined data across completed studies could further our understanding circulating DNA (ctDNA) as a marker and inform future trial design. We individual patient from three independent cohort nonmetastatic colorectal cancer (CRC). Plasma samples were collected 4 to 10 weeks Mutations assayed using massively parallel sequencing technique called...
107 Background: Recurrence rates following upfront resection of pancreatic adenocarcinoma are high, with some benefit from adjuvant chemotherapy (AC). A biomarker that improves risk stratification and/or provides real time indication AC could improve routine clinical management and accelerate trial progress. Previous studies in pancreas cancer suggest patients detectable ctDNA post surgery at an elevated recurrence. Detectable the completion may also be associated recurrence risk. Methods:...
3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric patients (pts) with previously treated MSI-H cancer regardless tumor type or site. This approval was based in part on data from cohort A phase 2 KEYNOTE-164 (NCT02460198) study pts CRC after ≥2 prior lines therapy including fluoropyrimidine, oxaliplatin, irinotecan. In addition, Cohort B KEYNOTE-164, we evaluated activity pembrolizumab metastatic ≥1 line therapy. Methods: enrolled CRC, status confirmed...
AimWe evaluated pembrolizumab monotherapy in patients with advanced salivary gland carcinoma on the phase 2 KEYNOTE-158 study (NCT02628067).MethodsEligible had histologically/cytologically confirmed prior failure or intolerance to standard therapy, measurable disease per Response Evaluation Criteria Solid Tumours (RECIST) v1.1., and ECOG performance status 0–1. Patients were enrolled irrespective of tumour PD-L1 expression. received 200 mg Q3W for up 35 cycles (∼2 years). Radiographic...
Background Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics pixatimod PD-1 inhibitor nivolumab in immunologically cold cancers. Methods 3+3 dose escalation with microsatellite stable metastatic colorectal cancer (MSS mCRC) pancreatic ductal adenocarcinoma (mPDAC) expansion cohorts. Participants received once weekly as 1-hour intravenous infusion plus every 2 weeks. Objectives included assessment antitumor...
108 Background: Previous results of the DYNAMIC study demonstrated that a ctDNA-guided approach versus standard management in stage II colon cancer (CC) reduced adjuvant chemotherapy (ACT) use without compromising 2-year recurrence-free survival (RFS). MMR status defines two distinct subsets CC. Here, we report impact ctDNA burden, end ACT (EOT) ctDNA, and updated data including overall (OS). Methods: is multi-center randomized phase trial. Eligible patients (pts) had resected CC were...
Abstract Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab FOLFIRI until progression intolerable toxicity. Mandatory tumor samples underwent mutation biomarker analysis. Efficacy analysis was conducted in RAS exon 2/3 tumors. Results: Of 134 randomly assigned patients, 98 had ex2/3 wild-type. provided no progression-free survival (PFS)...
Highlights•EMR 5-year survival >50%.•Docetaxel + CF improves histological responses for MNR.•DCF RT MNR.AbstractBackgroundPatients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer and rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients.Patients methodsPatients resectable EAC were enrolled randomised into two single-arm, multicentre phase II trials. After...